Siloton secures £860k seed investment to advance commercialisation of its eye imaging chip technology.
The funding round was backed by Evenlode Foundation alongside angel investors and a grant from Innovate UK.
Siloton is a Bristol-based health technology start-up developing miniature optical coherence tomography chips for eye imaging. The firm aims to make retinal disease monitoring more accessible for patients and healthcare providers.
Siloton has secured £860k in a seed investment round led by the Evenlode Foundation, with participation from Southeast Angels members, the Francis Crick Institute, and angel investors. The company also received non-dilutive backing from an Innovate UK Biomedical Catalyst grant, bringing its total funding to £1.7m. The capital will be used to advance the commercial roll-out and development of the Akepa optical coherence tomography chip technology, targeting a researcher release in 2025 and an upcoming live eye imaging milestone.
From the founder
"Siloton has brought together a uniquely qualified team that is able to drive forward technology development at an unprecedented pace. This new support will help us take the next step towards commercialisation by shifting gear from R&D to product development. The population of individuals with retinal disease is growing. New, more affordable and accessible OCT systems like our Akepa technology will be critical to serving patients with precision and efficiency. In turn, this could help reduce preventable blindness, save healthcare providers billions of pounds, and reduce pressure on already stretched eye clinics."
Alasdair Price
CEO at Siloton
Use of funds
- 01Continue product development
Investors
Categories
About the company
Siloton
Siloton develops miniature optical coherence tomography chips to improve eye imaging and retinal disease monitoring.